Cytoprotection against doxorubicin toxicity.
Perkins
T E
TE
Malkinson
F D
FD
Finnerud
C W
CW
D000970:Antineoplastic Agents / Q000009:adverse effects*; D004317:Doxorubicin / Q000009:adverse effects*; D006801:Humans; D011459:Prostaglandins E, Synthetic / Q000627:therapeutic use*; D012871:Skin Diseases / Q000139:chemically induced* / Q000517:prevention & control*
D000970:Antineoplastic Agents; D011459:Prostaglandins E, Synthetic; D004317:Doxorubicin